Generic drugmakers aren't wasting time anticipating Pfizer's loss of patent coverage on Lipitor. A handful of copycat drugmakers have filed with the FDA for approval of their versions of the blockbuster cholesterol drug. Report [1]
Links:
[1] http://money.cnn.com/news/newsfeeds/articles/djf500/200911060829DOWJONESDJONLINE000445_FORTUNE5.htm